Simplify Logo

Full-Time

Specialist

Training & Documentation

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$70k - $82kAnnually

Mid

Fitchburg, WI, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • Minimum of an Associate degree in applicable science field
  • Working knowledge of GMP, GCP, and/or GLP regulations
  • Competent knowledge of, and ability to use and format within Adobe Acrobat and Microsoft Office
Responsibilities
  • Manage employee’s training files and job descriptions within Arrowhead’s EDMS
  • Issue controlled forms, notebooks, etc
  • Assist with preparation, update, review, and routing of Arrowhead procedural documents
  • Assist QA management with the implementation and upkeep of a LMS (Learning Management System), including development and management of training curricula, driving consistency across departments, and ensuring access to proper leaning materials
  • Track and report on training compliance; notify management of over-due employee training requirements
  • Interact with personnel companywide to obtain the necessary information and details for preparing training records
  • Upload documents to Arrowhead’s EDMS, Veeva QualityDocs, and route for electronic approval
  • Scan and upload executed documents to the EDMS, properly categorize within the system, and route for verification/approval
  • Manage and ensure timely review of periodic review assignment within the EDMS
  • Write standard operating procedures and work instructions as needed for all types of quality systems and practices
  • Assist with Veeva and other system implementations
  • Assist with QA duties as needed
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.

Company Stage

IPO

Total Funding

$899.9M

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
  • Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
  • The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.

What critics are saying

  • The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
  • Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
  • The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
  • Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.